STOCK TITAN

Legend Biotech Corporation American Depositary Shares - LEGN STOCK NEWS

Welcome to our dedicated page for Legend Biotech Corporation American Depositary Shares news (Ticker: LEGN), a resource for investors and traders seeking the latest updates and insights on Legend Biotech Corporation American Depositary Shares stock.

Legend Biotech Corporation (Symbol: LEGN) is an emerging clinical-stage biopharmaceutical company dedicated to the development and commercialization of cutting-edge immunotherapy technology aimed at curing cancer. The company leverages its expertise in immunology and molecular biology to advance a robust pipeline of chimeric antigen receptor (CAR) product candidates designed to address a variety of liquid and solid tumors.

Legend Biotech's primary focus is on developing CAR-T cell therapies, which have shown great promise in clinical trials. One of their flagship products, LCAR-B38M/JNJ-4528, targets multiple myeloma, a previously incurable blood cancer. Recent clinical trial results have demonstrated significant success in treating patients with refractory and relapsed multiple myeloma, showcasing the potential of their proprietary CAR-T technology.

Founded with a vision to revolutionize cancer treatment, Legend Biotech aims to safely and effectively treat previously untreatable cancers with finely-tuned CAR-T products developed through their innovative technology platform. The company's ambition has been notably fulfilled by their advances in the CARs field, as evidenced by their promising clinical outcomes.

Legend Biotech collaborates extensively with leading immunologists and molecular biologists to enhance their research and development efforts. They generate significant revenue from license and collaboration agreements, primarily from the United States.

Stay updated with the latest news and developments regarding Legend Biotech Corporation on this dedicated page.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.18%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.38%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.53%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.61%
Tags
-
News
Rhea-AI Summary

Exelixis, Inc. (Nasdaq: EXEL) announced that Carl Feldbaum and Vincent Marchesi will not seek re-election to the Board of Directors during the 2023 Annual Meeting of Stockholders. The Board is nominating Tomas Heyman and Robert Oliver as independent directors to fill their positions. This decision follows unsuccessful settlement negotiations with Farallon Capital Management regarding board member nominations and access to company information. Dr. Stelios Papadopoulos expressed gratitude toward Feldbaum and Marchesi for their service. The upcoming board election aims to enhance corporate governance. Following the election, the Board will consist of 11 members, 10 of whom are independent. The Annual Meeting date has yet to be announced.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.26%
Tags
none
Rhea-AI Summary

Legend Biotech Corporation (NASDAQ: LEGN) has appointed Mythili Koneru, M.D., Ph.D. as its new Chief Medical Officer. Dr. Koneru previously served at Marker Therapeutics where she led the development of cell therapies and peptide vaccines. Her extensive background includes roles at Eli Lilly, focusing on immuno-oncology clinical development, and an oncology fellowship at Memorial Sloan-Kettering Cancer Center. CEO Ying Huang expressed confidence in Dr. Koneru's expertise in immunotherapy and cell therapy, emphasizing her role in advancing the company's pipeline. Dr. Koneru holds a B.A. in Cellular and Molecular Biology from the University of Chicago, a Ph.D. in Tumor Immunology from New York University, and an M.D. from Robert Wood Johnson Medical School.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.57%
Tags
management
-
Rhea-AI Summary

The report titled "Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2023" has been released by ResearchAndMarkets.com. This comprehensive report offers insights into partnering deals in the pharmaceutical and biotechnology sectors, including details on technology licensed, royalty rates, license fees, and other payments. It covers all disclosed deals since 2010, providing essential data for prospective dealmakers. Key chapters analyze royalty rate trends, the structure of royalty clauses, and leading companies in the field. The report aims to equip readers with the necessary tools for effective negotiations and due diligence in licensing agreements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

The CAR-T Therapy Pipeline Analysis Global Market Report 2023 has been released by ResearchAndMarkets.com, detailing significant growth in the CAR-T therapy market. The market is projected to expand from $1.40 billion in 2021 to $1.80 billion in 2022, reflecting a CAGR of 28.6%. By 2026, the market is expected to reach $3.55 billion, growing at a CAGR of 18.5%. Major players include Legend Biotech, Novartis AG, and Kite Pharma. The report highlights the role of financial support for CAR-T therapy development and notes the impact of high costs and limitations in treating certain cancers as challenges. The leading regions are North America and Western Europe, while the main product types include monotherapy and combination therapy targeting cancers such as acute lymphoblastic leukemia.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.91%
Tags
none
Rhea-AI Summary

Legend Biotech Corporation (NASDAQ: LEGN) has formed a new strategic advisory board, appointing Michel Vounatsos, former CEO of Biogen, and John Maraganore, PhD, former CEO of Alnylam Pharmaceuticals, as advisors. Both will collaborate with the company's leadership to enhance its cell therapy platforms and propel growth objectives. Vounatsos brings significant experience from Biogen and Merck, while Maraganore is recognized for his pivotal role in developing RNA interference therapeutics. The appointments aim to leverage their extensive industry backgrounds for advancing Legend Biotech's mission in treating life-threatening diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.66%
Tags
management

FAQ

What is the current stock price of Legend Biotech Corporation American Depositary Shares (LEGN)?

The current stock price of Legend Biotech Corporation American Depositary Shares (LEGN) is $32.8 as of December 24, 2024.

What is the market cap of Legend Biotech Corporation American Depositary Shares (LEGN)?

The market cap of Legend Biotech Corporation American Depositary Shares (LEGN) is approximately 6.0B.

What is Legend Biotech Corporation's main focus?

Legend Biotech focuses on developing and commercializing immunotherapy technology to treat various types of cancer.

What is CAR-T therapy?

CAR-T therapy involves modifying T cells to express chimeric antigen receptors that can target and destroy cancer cells.

What is Legend Biotech's lead product candidate?

Their lead product candidate is LCAR-B38M/JNJ-4528, a CAR-T cell therapy for treating multiple myeloma.

What types of cancer does Legend Biotech target?

Legend Biotech targets a wide range of liquid and solid tumors, with a significant focus on multiple myeloma.

Where does Legend Biotech generate most of its revenue?

The majority of Legend Biotech's revenue comes from the United States through license and collaboration agreements.

How successful have Legend Biotech's clinical trials been?

Their clinical trials have shown promising results, particularly in treating patients with refractory and relapsed multiple myeloma.

Who are Legend Biotech's collaborators?

Legend Biotech collaborates with leading immunologists and molecular biologists to advance their research and development.

What is the vision behind Legend Biotech's founding?

The company was founded on the vision of safely and effectively treating previously incurable cancers with innovative technology.

What is unique about Legend Biotech's technology platform?

Their platform focuses on developing finely-tuned CAR-T products, which have demonstrated significant clinical success.

How can I stay updated on Legend Biotech's latest news?

You can stay updated by following the latest news and developments on their dedicated page on StockTitan.

Legend Biotech Corporation American Depositary Shares

Nasdaq:LEGN

LEGN Rankings

LEGN Stock Data

6.02B
181.05M
1.31%
51.22%
12.49%
Biotechnology
Healthcare
Link
United States of America
Somerset